Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma.

被引：5
|
作者：
Mehmi, Inderjit [1 ,2 ]
Hill, Jordan [1 ,2 ]
机构：
[1] WVU Med, WVU Canc Inst, Morgantown, WV USA
[2] WVU Canc Inst WVU Med, Morgantown, WV USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21552
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma
    M. Amini-Adle
    N. Khanafer
    M. Le-Bouar
    G. Duru
    S. Dalle
    L. Thomas
    [J]. BMC Cancer, 18
  • [22] Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
    Bhave, Prachi
    Ahmed, Tasnia
    Lo, Serigne N.
    Shoushtari, Alexander
    Zaremba, Anne
    Versluis, Judith M.
    Mangana, Joanna
    Weichenthal, Michael
    Si, Lu
    Lesimple, Thierry
    Robert, Caroline
    Trojanello, Claudia
    Wicky, Alexandre
    Heywood, Richard
    Tran, Lena
    Batty, Kathleen
    Dimitriou, Florentia
    Stansfeld, Anna
    Allayous, Clara
    Schwarze, Julia K.
    Mooradian, Meghan J.
    Klein, Oliver
    Mehmi, Inderjit
    Roberts-Thomson, Rachel
    Maurichi, Andrea
    Yeoh, Hui-Ling
    Khattak, Adnan
    Zimmer, Lisa
    Blank, Christian U.
    Ramelyte, Egle
    Kaehler, Katharina C.
    Roy, Severine
    Ascierto, Paolo A.
    Michielin, Olivier
    Lorigan, Paul C.
    Johnson, Douglas B.
    Plummer, Ruth
    Lebbe, Celeste
    Neyns, Bart
    Sullivan, Ryan
    Hamid, Omid
    Santinami, Mario
    McArthur, Grant A.
    Haydon, Andrew M.
    Long, Georgina, V
    Menzies, Alexander M.
    Carlino, Matteo S.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)
  • [23] Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma
    Amini-Adle, M.
    Khanafer, N.
    Le-Bouar, M.
    Duru, G.
    Dalle, S.
    Thomas, L.
    [J]. BMC CANCER, 2018, 18
  • [24] Optimizing PD-1 to PD-L1 proximity assays to predict response in patients with advanced melanoma receiving anti-PD-1
    Green, B.
    Will, E.
    Engle, L.
    Deutsch, J. S.
    Lipson, E.
    Szalay, A.
    Sunshine, J. C.
    Taube, J.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S32 - S32
  • [25] Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma
    Wang, Daniel Y.
    Eroglu, Zeynep
    Ozgun, Alpaslan
    Leger, Paul D.
    Zhao, Shilin
    Ye, Fei
    Luke, Jason J.
    Joseph, Richard W.
    Haq, Rizwan
    Ott, Patrick A.
    Hodi, F. Stephen
    Sosman, Jeffrey A.
    Johnson, Douglas B.
    Buchbinder, Elizabeth I.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2017, 5 (05) : 357 - 362
  • [26] Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure
    Klee, Gina
    Kurzhals, Jonas
    Hagelstein, Victoria
    Zillikens, Detlef
    Recke, Andreas
    Langan, Ewan A.
    Terheyden, Patrick
    [J]. MELANOMA RESEARCH, 2021, 31 (05) : 464 - 471
  • [27] ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
    Butler, M. O.
    Robert, C.
    Negrier, S.
    In, G. K.
    Walker, J.
    Krajsova, I.
    Atkinson, V. G.
    Hansson, J.
    Kapiteijn, E.
    Loquai, C.
    Shaw, H. M.
    Cheng, T.
    Mansard, S.
    Grob, J. J.
    Guidoboni, M.
    Mehta, M.
    Ascierto, P. A.
    Diab, A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [28] Tumor growth rate as an early indicator of the efficacy of anti-PD-1 immunotherapy in advanced melanoma.
    Tang, Bixia
    Chi, Zhihong
    Sheng, Xinan
    Si, Lu
    Cui, Chuanliang
    Kong, Yan
    Yan, Xieqiao
    Li, Siming
    Mao, Lili
    Lian, Bin
    Wang, Xuan
    Bai, Xue
    Zhou, Li
    Dai, Jie
    Guo, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Efficacy of anti-CTLA-4 after progression on anti-PD1 therapy in advanced melanoma
    Aya Moreno, F.
    Fernandez-Martinez, A.
    Gaba, L.
    Victoria, I.
    Arance Fernandez, A. M.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 6 - 6
  • [30] Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
    Peng, Ye
    Zeng, Xiaohui
    Peng, Liubao
    Liu, Qiao
    Yi, Lidan
    Luo, Xia
    Li, Sini
    Wang, Liting
    Qin, Shuxia
    Wan, Xiaomin
    Tan, Chongqing
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
12345